HRG-β1 inhibitors are a specialized class of compounds that act by modulating the activity of the HRG-β1 protein, which is involved in a variety of cellular signaling processes. These inhibitors typically function by binding to the HRG-β1 protein or its associated receptors, disrupting its interaction with other proteins or ligands necessary for its normal activity. Structurally, HRG-β1 inhibitors can range from small molecules to larger, more complex compounds such as peptides. The design of these inhibitors often incorporates key functional groups that enable strong binding interactions, such as hydrogen bonds, van der Waals forces, and electrostatic interactions with the target protein or receptor. This binding blocks HRG-β1's ability to engage in its usual role in signal transduction, thereby inhibiting downstream biological processes associated with its activity.
From a chemical perspective, HRG-β1 inhibitors are optimized for stability and selectivity. They are often engineered to resist degradation under various conditions, including enzymatic or oxidative breakdown, which ensures that they retain their inhibitory function in different environments. These compounds also exhibit diverse physical properties, such as solubility and permeability, which are important considerations for their effective interaction with the HRG-β1 target in biological systems. Additionally, the kinetics of HRG-β1 inhibitors can vary, with some showing rapid, reversible binding, while others form more prolonged, potentially irreversible interactions with their target. These characteristics are fine-tuned through careful chemical synthesis and structural modification to achieve the desired inhibitory effect, with the ultimate goal of efficiently disrupting HRG-β1 activity at a molecular level.
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | ¥226.00 ¥463.00 | 4 | |
抑制环氧化酶,可能会影响炎症和凝血途径。 | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | ¥812.00 ¥1828.00 | 7 | |
抑制依赖维生素 K 的凝血因子,可能会改变凝血途径。 | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | ¥1749.00 | 18 | |
直接抑制因子 Xa,可能会影响与 HRG-β1 功能相关的凝血级联反应。 | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | ¥2651.00 ¥7017.00 | 2 | |
Xa 因子抑制剂可能会改变凝血酶的形成并影响相关的信号通路。 | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | ¥1354.00 | 1 | |
抑制血小板上的 P2Y12 ADP 受体,可能影响血小板聚集和相关途径。 | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | ¥282.00 ¥1320.00 ¥2358.00 | 27 | |
酪氨酸激酶抑制剂可影响与细胞生长和粘附有关的细胞信号通路。 | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | ¥1692.00 ¥10379.00 | 5 | |
抑制多种受体酪氨酸激酶,可能影响血管生成和相关信号传导。 | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | ¥857.00 ¥925.00 ¥4140.00 | 36 | |
调节炎症的糖皮质激素,可能影响免疫反应途径。 | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | ¥1038.00 ¥2358.00 | 33 | |
抑制二氢叶酸还原酶,可能影响细胞增殖和免疫功能。 | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | ¥632.00 | 1 | |
调节免疫活动,可能会影响与炎症和自身免疫相关的途径。 |